◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › ASND

Ascendis Pharma AS (ASND) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-07-25

Ascendis Pharma AS (ASND) operates in the BIOTECHNOLOGY industry and is headquartered in Hellerup, Denmark with about 1,189 employees. Its market capitalization is roughly $17 billion. In the fiscal year ended 2025-12-31, ASND reported $692M in revenue and ($219M) in net income.

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.

Interactive charts & full statements → Open the ASND valuation workbench →

ASND Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$868M	$692M	$364M	$267M	$51M	$8M	$7M	$13M	$11M	$2M	$5M	$8M	$14M	$20M	$16M
Gross Profit	$765M	$589M	$319M	$222M	$39M	$4M	$7M	$13M	$11M	$2M	$5M	$8M	$14M	$20M	$16M
Gross Margin %	88.2%	85.1%	87.8%	83.4%	76.3%	54.7%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($7M)	($131M)	($279M)	($456M)	($562M)	($452M)	($331M)	($227M)	($155M)	($112M)	($73M)	($42M)	($12M)	$5M	$2M
Operating Margin %	-0.8%	-18.9%	-76.7%	-170.8%	-1097.9%	-5808.6%	-4755.1%	-1695.1%	-1462.6%	-7290.3%	-1583.2%	-515.2%	-85.7%	25.9%	9.7%
Net Income	$507M	($219M)	($378M)	($481M)	($583M)	($384M)	($419M)	($218M)	($130M)	($124M)	($69M)	($33M)	($10M)	$4M	$1M
Net Margin %	58.4%	-31.7%	-104.0%	-180.5%	-1139.6%	-4931.6%	-6025.5%	-1630.0%	-1229.5%	-8097.8%	-1487.3%	-405.5%	-69.1%	20.0%	8.0%
EBITDA	$12M	($110M)	($290M)	($411M)	($529M)	($365M)	($408M)	($210M)	($150M)	($110M)	($72M)	($33M)	($11M)	$6M	$2M
Earnings Per Share (EPS)	$7.76	$-3.61	$-6.53	$-8.55	$-10.40	$-7.00	$-8.28	$-4.69	$-3.17	$-3.68	$-2.58	$-1.39	$-0.57	$0.38	$0.12
Shares Outstanding (M)	65M	61M	58M	56M	56M	55M	51M	47M	41M	34M	27M	24M	17M	11M	11M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASND Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$251M	$245M	$214M	$158M	$101M	$174M	$58M	$36M
Gross Profit	$229M	$218M	$191M	$127M	$83M	$160M	$47M	$25M
Gross Margin %	91.4%	88.9%	89.5%	80.1%	82.7%	91.9%	80.6%	68.2%
Operating Income (EBIT)	$25M	$10M	$11M	($53M)	($104M)	$0M	($97M)	($133M)
Operating Margin %	10.1%	4.0%	5.1%	-33.5%	-103.2%	0.2%	-167.3%	-370.2%
Net Income	$640M	($33M)	($61M)	($39M)	($95M)	($38M)	($99M)	($109M)
Net Margin %	255.2%	-13.6%	-28.5%	-24.6%	-93.7%	-22.1%	-171.5%	-303.9%
EBITDA	$24M	$40M	($53M)	$2M	($44M)	($38M)	($71M)	($88M)
Earnings Per Share (EPS)	$9.91	$-0.54	$-1.00	$-0.61	$-1.58	$-0.64	$-1.69	$-1.91
Shares Outstanding (M)	65M	61M	61M	64M	60M	60M	59M	57M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASND Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cash from Operations (CFO)	$58M	$52M	($306M)	($467M)	($496M)	($418M)	($272M)	($176M)	($139M)	($95M)	($60M)	($43M)	($18M)	$6M	($1M)
Capital Expenditures (CapEx)	$16M	$8M	$1M	$2M	$14M	$24M	$22M	$5M	$3M	$1M	$1M	$1M	$0M	$1M	$0M
Free Cash Flow (FCF)	$42M	$44M	($308M)	($470M)	($510M)	($442M)	($293M)	($181M)	($141M)	($96M)	($61M)	($45M)	($19M)	$5M	($1M)
FCF Margin %	4.9%	6.3%	-84.6%	-176.1%	-997.0%	-5681.2%	-4215.4%	-1354.0%	-1336.8%	-6277.1%	-1321.1%	-548.2%	-134.5%	25.1%	-6.0%
Dividends Paid	—	—	—	—	$5M	$33M	—	$0M	$0M	$0M	$0M	$0M	$0M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASND Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	($8M)	$71M	$2M	($7M)	($14M)	($87M)	($56M)	($61M)
Capital Expenditures (CapEx)	$8M	$3M	$0M	$4M	$1M	$0M	$0M	$0M
Free Cash Flow (FCF)	($16M)	$67M	$2M	($12M)	($15M)	($88M)	($57M)	($62M)
FCF Margin %	-6.3%	27.5%	1.0%	-7.4%	-14.9%	-50.3%	-97.9%	-171.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASND Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$2.0B	$1.3B	$1.2B	$826M	$1.1B	$1.1B	$980M	$677M	$319M	$211M	$190M	$132M	$59M	$27M	$25M	$23M
Cash & Cash Equivalents	$573M	$616M	$560M	$392M	$445M	$446M	$585M	$598M	$278M	$195M	$180M	$120M	$50M	$19M	$15M	$16M
Total Liabilities	$1.5B	$1.5B	$1.3B	$971M	$826M	$201M	$141M	$80M	$39M	$24M	$13M	$11M	$13M	$20M	$24M	$23M
Total Debt (Short + Long-Term)	$897M	$872M	$857M	$970M	$910M	$112M	$7M	$6M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$488M	($163M)	($106M)	($146M)	$263M	$884M	$839M	$597M	$280M	$187M	$177M	$120M	$46M	$6M	$2M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ASND viewer.

Other Companies in BIOTECHNOLOGY

ALNY · Alnylam Pharmaceuticals Inc — $36 billion
RPRX · Royalty Pharma Plc — $34 billion
ROIV · Roivant Sciences Ltd — $25 billion
INSM · Insmed Inc — $23 billion
BBIO · BridgeBio Pharma Inc — $16 billion
JAZZ · Jazz Pharmaceuticals PLC — $16 billion
EXEL · Exelixis Inc — $14 billion
MDGL · Madrigal Pharmaceuticals Inc — $13 billion

← ASML All stocks ASO →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.